Highlights a novel CRISPR/Cas9-based tool for targeted genetic modification specifically in cardiomyocytes post-birth, enabling new animal models for cardiovascular research.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
James et al. (2016) reported an editorial. Cardioediting (CRISPR-Cas9 and AAV-delivered sgRNA) was evaluated on Gene editing at the myh6 locus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: